Dasiglucagon

Summary

Dasiglucagon (CHEMBL4297741) is a phase-3 clinical-stage unknown (ATC H04AA02); indicated across 4 conditions including hypoglycemia and hyperinsulinemic hypoglycemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: H04AA02
• Indications: 4 conditions
• Clinical trials: 22

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297741
Name	Dasiglucagon
Type	Unknown
Max phase	3
ATC	H04AA02

Also known as: Dasiglucagon, ZP-4207, ZP-GA-1, ZP4207, DASIGLUCAGON

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypoglycemia	3	MONDO:0004946	HP:0001943
hyperinsulinemic hypoglycemia	2	MONDO:0005803	EFO:0007318
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 22.

Phase distribution

Phase	Trials
PHASE3	8
PHASE2	8
PHASE1	4
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03941236	PHASE3	ACTIVE_NOT_RECRUITING	Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
NCT03216226	PHASE3	COMPLETED	A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
NCT03378635	PHASE3	COMPLETED	A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
NCT03667053	PHASE3	COMPLETED	Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
NCT03688711	PHASE3	COMPLETED	Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
NCT03777176	PHASE3	COMPLETED	A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
NCT03840278	PHASE2/PHASE3	COMPLETED	The Bihormonal iLet Bionic Pancreas Feasibility Study
NCT03895697	PHASE3	COMPLETED	A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM
NCT04172441	PHASE2/PHASE3	COMPLETED	Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
NCT05378672	PHASE3	COMPLETED	A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
NCT02660008	PHASE2	COMPLETED	Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon
NCT02971228	PHASE2	COMPLETED	Feasibility Trial Testing the Bionic Pancreas With ZP4207
NCT03984370	PHASE2	COMPLETED	Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass
NCT04449692	PHASE2	COMPLETED	Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes
NCT04764968	PHASE2	COMPLETED	Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes
NCT04824872	PHASE2	WITHDRAWN	Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults
NCT04836273	PHASE2	COMPLETED	Treatment of Post-bariatric Hypoglycaemia
NCT05454709	PHASE2	WITHDRAWN	A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
NCT02367053	PHASE1	COMPLETED	Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator
NCT02390141	PHASE1	COMPLETED	Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207
NCT03735225	PHASE1	COMPLETED	Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration
NCT06588504	PHASE1	COMPLETED	Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).